This morning, experts delivered "short and sweet" updates on treatment strategies for common dermatologic conditions. This content was developed independently and is not endorsed by the American ...
Experts at the 2026 AAD Annual Meeting urged dermatologists to engage in advocacy to protect practices and patient access amid growing challenges. Klint Peebles, MD, FAAD, a dermatologist with the Mid ...
Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa. This content was developed independently and is not ...
April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD. This content was developed ...
Topical immunotherapy remains an effective, affordable option for alopecia areata, with long-term control seen in multimodal treatment approaches. Topical immunotherapy continues to have a significant ...
Despite its relevance to prognosis and treatment response, baseline disease duration is inconsistently reported in phase 3 clinical trials for chronic spontaneous urticaria (CSU), ...
New research is helping to change the way investigators and clinicians think about and treat Richter transformation (RT) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic ...
Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results